Electronic Nose Sniffs Out Prostate Cancer Using Urine Samples

Novel noninvasive technique successfully discriminates between prostate cancer and benign disease in proof of principle study, paving the way for easy and early diagnosis, reports The Journal of Urology

We may soon be able to make easy and early diagnoses of prostate cancer by smell. Investigators in Finland have established that a novel noninvasive technique can detect prostate cancer using an electronic nose. In a proof of principle study, the eNose successfully discriminated between prostate cancer and benign prostatic hyperplasia (BPH) by “sniffing” urine headspace (the space directly above the urine sample). Results using the eNose are comparable to testing prostate specific antigen (PSA), reports The Journal Of Urology.

Prostate cancer is the second most common cancer in males and one of the leading causes of cancer death. The heterogeneity of prostate cancer makes it difficult to diagnose and predict tumor progression. Both of the current cornerstones of diagnosis, i.e. digital rectal examination (DRE) and PSA have limitations, while ultrasound guided biopsies are costly, uncomfortable for the patient, and have a risk of infection. Additionally, significant numbers of diagnosed prostate cancers are of low grade and will not cause symptoms or disease-specific mortality. Therefore, aggressive treatment can lead to decreased quality of life without extending the patient’s life. Thus, there is a need for novel diagnostic tools.

In the 1980s incidental reports of dogs that detected cancer in their owners sparked a number of experimental studies that have since confirmed that trained sniffer dogs can detect cancer. However, variations in the performance of dogs during and between studies have meant that these findings are of limited application. A more promising development is the growth of sensor technology (generally referred to as artificial olfaction) that has led to the invention of numerous new types of olfactory electronic sensors.

eNoses are best suited for qualitative analysis of complex gaseous mixtures of molecules, and are routinely used in food and agricultural quality control and military applications. The eNose used in the current study is a device that consists of a cluster of nonspecific sensors. When the device is exposed to the sample, it produces a profile or a “smell print.”

“eNoses have been studied in various medical applications, including early detection of cancer, especially from exhaled air,” says lead investigator Niku KJ. Oksala, MD, PhD, DSc, of the Department of Surgery, School of Medicine, University of Tampere and Department of Vascular Surgery, Tampere University Hospital, Finland. “However, exhaled air is a problematic sample material since it requires good cooperation and technique from the patient and immediate analysis, while urine is simple to attain and store, and is therefore more feasible in clinical practice. Preliminary data suggested that detection of urologic malignancies from urine headspace was possible. Our own preliminary results on prostate cancer cells encouraged us to launch this prospective clinical study.”

The ChemPro 100–eNose (Environics Inc., Mikkeli, Finland) was tested on 50 patients who had been diagnosed with prostate cancer confirmed by biopsy, and 15 patients with BPH. Both groups were scheduled for surgery. The patients provided urine samples before surgery and those with benign disease also provided samples three months after surgery to be used as a pooled control sample population. Patients with prostate cancer underwent robotic assisted laparoscopic radical prostatectomy, while the benign disease group underwent transurethral resection of prostate.

Results with the eNose confirmed that using urine headspace, the eNose is able to discriminate prostate cancer from BPH. The eNose achieved a sensitivity of 78%, specificity of 67% and AUC of 42.0.

“The performance with the eNose matches that of PSA results in previous literature and the results are achieved rapidly and in a completely noninvasive manner,” comments Dr. Oksala. “PSA is known to correlate positively with prostate volume, which is a potential source of diagnostic error when comparing prostate cancer with benign disease. According to our current analysis, prostate volume did not affect the eNose results, potentially indicating high specificity of our sensor array to cancer. We also studied whether eNose signal correlates with the size of the tumor. No such correlation was found. Further studies are now warranted to enhance current technology and to identify the molecules behind the distinct odors.”

“Detection of prostate cancer by an electronic nose: A proof of principle study,” by Antti Roine, Erik Veskimäe, Antti Tuokko, Pekka Kumpulainen, Juha Koskimäki, Tuomo A. Keinänen, Merja R. Häkkinen, Jouko Vepsäläinen, Timo Paavonen, Jukka Lekkala, Terho Lehtimäki, Teuvo L. Tammela, and Niku K.J. Oksala. DOI: http://dx.doi.org/10.1016/j.juro.2014.01.113. The Journal of Urology, Volume 192, Issue 1 (July 2014) published online in advance of issue by Elsevier.

About The Journal of Urology
Established in 1917, The Journal of Urology (www.jurology.com) is the official journal of the American Urological Association (www.auanet.org). It is the most widely read and highly cited journal in the field. It brings to its readership all the clinically relevant information needed to stay at the forefront of this dynamic field. This top-ranking journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide and practice-oriented reports on interesting clinical observations.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV.